ProShares Ultra Nasdaq Biotechnology (BIB)

  • Loading...

Fund Description

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®. The fund invests in securities and derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times (2x) the daily return of the index. The index is a modified capitalization weighted index that includes securities of NASDAQ listed companies that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark ("ICB") which also meet other eligibility criteria determined by NASDAQ. The fund is non-diversified.

Fund Snapshot Updated 07.21.2014

Previous Close $88.17 Expense Ratio 0.95%
YTD Return 17.19% Avg. 30-Day Volume 239,696
1-Year Return 52.9% Market Cap Loading...
Bid $88.10 Shares Outstanding 3,850,000
Ask $88.23 Dividends $0.00
Top 10 Holdings
Celgene Corp (CELG) 8.51%
Gilead Sciences Inc (GILD) 8.35%
Amgen Inc (AMGN) 7.83%
Biogen Idec Inc (BIIB) 7.23%
Alexion Pharmaceuticals Inc (ALXN) 6.85%
Vertex Pharmaceuticals Inc (VRTX) 5.08%
Illumina Inc (ILMN) 4.24%
Mylan Inc (MYL) 3.93%
Regeneron Pharmaceuticals (REGN) 3.78%
Endo Intl Plc (ENDP) 2.39%
% of Total Holdings 58.20%

Sector Breakdown

Geographic Breakdown

Best Fit Health/Biotechnology Funds

See full rankings for Health/Biotechnology Funds